Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05652686
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:16.377860+00:00
Published At
2025-09-23T00:00:00+00:00
Record Updated At
2025-09-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Small Cell Lung Cancer (SCLC)", "Large Cell Neuroendocrine Cancer (LCNEC)", "Neuroendocrine Prostate Cancer (NEPC)", "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)", "Neuroendocrine Carcinomas (NEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-23"
protocolSection.identificationModule.nctId
"NCT05652686"
protocolSection.identificationModule.officialTitle
"An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Small Cell Lung Cancer (SCLC) (protocolSection.conditionsModule.conditions)
  • Large Cell Neuroendocrine Cancer (LCNEC) (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Prostate Cancer (NEPC) (protocolSection.conditionsModule.conditions)
  • Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Carcinomas (NEC) (protocolSection.conditionsModule.conditions)
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.